Noe går an å finne, her er presentasjoner fra tidligere selskaper:
Published on: 15/10/09
MorphoSys has appointed Dr Lisa Rojkjaer as vice president and head of clinical development.
Dr Rojkjaer joins MorphoSys from Novartis where she most recently held the position of head of medical affairs - hematology, Europe.
Before that she was global clinical programme head for Exjade, where she was responsible for all clinical activities in Europe for Novartis’ haematology portfolio including Gleevec and Exjade.
Prior to Novartis, she spent five years with Novo Nordisk, in Copenhagen, Denmark, and Princeton, USA as the director of global medical affairs biopharmaceuticals and later director, clinical development haematology.
During her time with Novo Nordisk she established a global medical affairs group for biopharmaceuticals and headed the clinical development of the US haematology portfolio amongst other accomplishments.
Dr Rojkjaer is a board certified haematologist and received her medical degree from the University of Toronto, where she also did her residency in internal medicine and fellowship in haematology.
She has held academic and hospital appointments in the US, Canada and Europe.
May 31, 2012 07:10 AM Eastern Daylight Time
ZURICH-SCHLIEREN, Switzerland–(BUSINESS WIRE)–Molecular Partners AG, the leader in the discovery and development of DARPins®, a novel class of therapeutic proteins, today announced the appointment of Lisa Rojkjaer, MD as Chief Medical Officer, strengthening the existing management team.
Dr. Rojkjaer holds a medical degree from the University of Toronto and is a board-certified hematologist with over 10 years experience in drug development and commercialization in the biotech and pharma industries. She will be heading up all clinical activities at Molecular Partners by identifying and prioritizing clinical development programs of Molecular Partners in order to broaden the company’s pipeline.
Commenting on the appointment, Dr. Christian Zahnd, CEO of Molecular Partners said: “We are delighted that Lisa is joining us to head up the clinical activities at Molecular Partners. She brings a wealth of knowledge and experience in the full development of biologics. With her excellent understanding of the translational and later clinical development phases and her experience on the expectations of the market, Lisa will further strengthen and complement our existing management team.”
Prior to joining Molecular Partners, Dr. Rojkjaer led all proprietary clinical development programs as Vice President and Head of Clinical Development at Morphosys AG in Germany. Previously, Dr. Rojkjaer held a variety of senior positions in clinical development and medical affairs. She served as a Global Clinical Program Head in oncology development, and more recently as EU Head of Medical Affairs, Hematology at Novartis. Prior to Novartis, she spent five years with Novo Nordisk as the Head of Global Medical Affairs, Biopharmaceuticals in Denmark and later, Director of Clinical Development, Hematology in the US. In these positions, Dr. Rojkjaer was responsible for development of products and product candidates in early and late (phase I-IV) development stages.
Commenting on her appointment, Dr. Rojkjaer said: “I am very excited to be joining Molecular Partners, as only few companies have the ability to generate a pipeline of novel differentiated and very versatile compounds to truly improve patient outcomes in a variety of disease areas. I look forward to being a part of advancing these novel compounds into the clinic and beyond.”
